In our study, PTs of nasopharyngitis (PT: 10028810), upper respiratory tract infection (PT: 10046306), pharyngitis (PT: 10034835), lower respiratory tract infection (PT: 10024968), rhinorrhoea (PT: 10039101), oral herpes (PT: 10067152), oral candidiasis (PT: 10030963), inflammatory bowel disease (PT: 10021972), external ear inflammation (PT: 10065837), middle ear inflammation (PT: 10065838), skin exfoliation (PT: 10040844), C-reactive protein increased (PT: 10006825) and uveitis (PT: 10046851) were presented, which were indicated in the label for secukinumab. This evidence concerns the gene CRP and uveitis.